RBR-72wbbg招募中未知
ongterm follow-up of subjects with cerebral Adrenoleukodystrophy who were treated with Lenti-D drug product
Blanchard y Asociados0 个研究点开始时间: 2020年3月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0Y 至 19Y（—）
- 性别
- Male
入选标准
- •Provision of written informed consent for this study by the subject or subject’s parent(s)/legal guardian(s) and written informed assent by subject, if applicable. Have received Lenti-D Drug Product in a parent clinical study. Able to comply with study requirements
排除标准
- •There are no exclusion criteria for this Study.
研究者
相似试验
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductCerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code: 10051260Term: Adrenoleukodystrophy Class: 100000004850MedDRA version: 20.0Level: SOCClassification code: 10010331Term: Congenital familial and genetic disorders Class: 21CTIS2024-513904-33-00Bluebird Bio Inc.64
招募中
3 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductCALDcerebral adrenoleukodystrophy10029299NL-OMON54368bluebird bio, Inc.3
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductEUCTR2015-002805-13-DEbluebird bio, Inc67
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductEUCTR2015-002805-13-NLbluebird bio, Inc60
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductCerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002805-13-FRbluebird bio, Inc.25